Company* |
Company* |
Product |
Terms/Details (Date) |
| |||
Albany Molecular Research Inc. |
Seattle Genetics |
Albany Molecular will manufacture the drug- |
Clinical trials of the antibody-drug conjugate are expected to begin in 2006; the deal also provides licensees of Seattle Genetics' ADC technology to work directly with Albany Molecular to obtain drug-linkers for their own trials (5/5) |
BioReliance |
Acambis plc | Acambis acquired a U.S.- based fill/finish facility, where it will manufacture vaccines |
BioReliance gets $3M up front and another $4.5M over 12 years; Acambis will assume responsibility for the 12-year lease (5/9) |
Capital Genomix |
SpectruMedix | Worldwide deal to market and sell the GeneSystem-320 for capillary electrophoresis-based applications. |
The companies intend to launch the product in 3Q:05; terms were not disclosed (5/4) |
Cobra Bio- manufacturing |
Synco |
Collaboration to manufacture plasmid DNA for Phase III trials and commercial supply |
Synco licensed rights related to the pDNA manufacturing process; they also will work together on marketing of their pDNA manufacturing services (5/4) |
Gene Bridges |
Covalys |
Deal to develop DNA engineering kits to generate SNAP-tag fusion proteins |
The work is based on Gene Bridges' Red/ET recombination technology; the cloning kits are expected to be on the market in 3Q:05 (6/14) |
Inte:Ligand | Molecular |
Deal to integrate |
Ilib Diverse is a virtual compound library- generation platform; they also plan to share complementary technologies in the future (4/26) |
Invitrogen | Applied |
Co-marketing deal to sell a combined collection of labeling technologies |
The products include ABI's iTRAQ and ICAT reagents and Invitrogen's SILAC technology; ABI also will provide software support for SILAC; terms were not disclosed (6/6) |
Lorantis |
Althea |
Althea will manufacture the protein component of Lorantis' HepVax, a hepatitis B therapeutic vaccine |
Althea will provide a range of services under the contract as the product advances toward clinical evaluation; terms were not disclosed (4/27) |
Luminex Corp. |
EraGen |
The companies entered an expanded licensing and distribution agreement |
EraGen got rights to sell Luminex 100 Systems and kits that include nonstandard nucleic acid bases, proprietary to EraGen, designed for certain in vitro clinical diagnostic purposes (4/26) |
Primus Pharmaceuticals | CollaGenex Pharmaceuticals |
Deal under which CollaGenex will promote Alcortin and Novacort to dermatologists in the U.S. |
Alcotrin is a topical antifungal steroid combination; Novacort is a topical steroid and anesthetic; terms of the deal were not disclosed (6/8) |
Procognia |
Qiagen NV |
Qiagen got exclusive rights to market Procognia's "on-chip" protein glycoanalysis technology |
The products will be combined with Qiagen's QProteome product line; terms of the deal were not disclosed (5/16) |
Protein | ViRexx Medical |
Deal under which PSC will manufacture ViRexx's lead Chimigen vaccine, HepaVaxx B |
Phase I trials of the hepatitis B vaccine are expected to begin in 3Q:05; terms of the deal were not disclosed (4/28) |
Proteos Inc.* |
DNAPrint Genomics Inc. |
Proteos will manufacture DNAP's PT-401 (Super EPO dimer) for preclinical testing |
Terms of the deal were not disclosed (5/14) |
StemCo | StemCell Technologies* (Canada) |
Worldwide deal under which StemCell will distribute StemCo's Aldefluor product |
Aldefluor is a kit that enables the identification of stem and progenitor cells; StemCell previously had rights only in the Americas and much of the Asia-Pacific region (6/9) |
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
LSE = London Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange. |